Reference, (na) | Treatment regimen | Response rate (%)b | Progression-free survival | |||
---|---|---|---|---|---|---|
 |  | CR | PR | SD | Median | At 6 months (%) |
Bevacizumab | Â | Â | Â | Â | Â | Â |
Vredenburgh [28], (n = 23 of 32)d | BV + irinotecan | 4 | 57 | 35 | 20 weeks | 30 |
Vredenburgh [29], (N = 35) | BV + irinotecan | 57 | N/A | 24 weeks | 46 | |
Narayana [33], (n = 37 of 61)e | BV + irinotecan or carboplatin | 13 | 60 | 21 | 5 months | N/A |
BV alone (n = 85) BV + irinotecan (n = 82) | 28 38 | N/A N/A | 4.2 months 5.6 months | 43 50 | ||
Reardon [38], (n = 27 of 59)d | BV + etoposide | 4 | 19 | 70 | 18 weeks | 44 |
Kreisl [49], (N = 48) | BV → BV + irinotecan | 71 (Levin criteria); 35 (MacDonald criteria) | N/A | 16 weeks | 29 | |
Gutin [92], (n = 20 of 25)d | BV + hypofractionated stereotactic irradiation | 50 | N/A | 7.3 months | 65 | |
Aflibercept | Â | Â | Â | Â | Â | Â |
De Groot [53], (n = 32 of 48)d | Aflibercept alone | 0 | 30 | 52 | N/A | N/A |
Cediranib | Â | Â | Â | Â | Â | Â |
Batchelor [112], (N = 31) | Cediranib alone | 57 (volumetric criteria); 27 (MacDonald criteria) | N/A | 117 days | 26 | |
Cilengitide | Â | Â | Â | Â | Â | Â |
Reardon [50] (N = 81) | Cilengitide alone (2000 mg/d [n = 40] or 500 mg/d [n = 41]) | 0 | 9 | N/A | 2000 mg/d, 8.1 weeksc 500 mg/d, 7.9 weeksc | 2000 mg/d, 15 500 mg/d, 10 |
CT-322 | Â | Â | Â | Â | Â | Â |
Schiff [113], (n = 51) | CT-322 alone (n = 33) CT-322 + irinotecan (n = 18) | 1 (3) 0 | 1 (3) 0 | N/A N/A | N/A N/A | 23 48 |
XL184 | Â | Â | Â | Â | Â | Â |
Wen [54], (n = 105) | XL184 175 mg qd XL 184 125 mg qd | AAT-naive (n = 34), 21 AAT-pretreated (n = 12), 8 AAT-naive (n = 37), 30 AAT-pretreated (n = 22), 0 | N/A | AAT-naive, 16 weeks AAT-naive, 16 weeks AAT-pretreated, 7.9 weeks | AAT-naive, 10 AAT-naive, 25 AAT-pretreated, 0 |